Hanover - Brunswick

Antibiotics Screening and Hit Generation

Mark Brönstrup’s research group aims to identify and optimise new antibacterial and antiviral agents. They therefore test collections of various compounds using newly developed assay systems and are expanding the DZIF infrastructure in collaboration with the European network EU OPENSCREEN. In ...

Heidelberg

Biosafety Level 3 Imaging Platform for HIV Research

The imaging platform in Heidelberg offers scientists the most up-to-date microscopes and imaging techniques. It enables the observation of pathogenic processes both in complex tissues and in vivo. This platform was designed to accommodate biosafety levels BSL 2 and 3, both of which are important for ...

Gießen - Marburg - Langen

Biosafety Level 4 Laboratory in Marburg

When emerging viruses cause severe diseases, the rapid development of vaccines and antivirals against these pathogens becomes critical. Some newly emerging viruses are very dangerous and necessitate the highest of biosafety levels for research and development purposes. DZIF scientists have a ...

Hanover - Brunswick

CEGIMIR: Centre for GI Microbiome Research

The know-how for microbiome analysis coalesces at the Centre for GI Microbiome Research (CEGIMIR). The gastrointestinal microbiome, i.e. all the microorganisms in the gastrointestinal tract, plays a key role in the course of infections. Changes in composition, such as those caused by environmental ...

Hanover - Brunswick

Centre for Gastrointestinal Clinical Trials (CEGICLIN)

CEGICLIN is a virtual centre for gastrointestinal clinical trials. Study nurses from this centre are available to the three DZIF Partner Sites involved in this area of research. The Centre also collaborates closely with the DZIF’s clinical trial units and regional clinical trial centres. This ...

Hamburg - Lübeck - Borstel - Riems

Clinical Management, Epidemiology and Immunology of Newly Emerging Infections

This research group, led by Professor Marylyn Addo, initiates and coordinates translational research in the field of emerging infections with a particular focus on Ebola, MERS, Lassa and Crimean-Congo haemorrhagic fever. Immunology studies, vaccine development, testing of novel anti-infectives and ...

Tübingen

Clinical Research Group in Lambaréné

The CERMEL (Centre de Recherche Médical de Lambaréné) in Gabon is one of the leading establishments for malaria research in Africa. Clinical trials on vaccines and agents are tested according to the same approved guidelines that are used in Germany. A clinical research group was established within ...

Tübingen

Clinical Research Unit "Healthcare-associated Infections"

The clinical research unit led by Prof. Evelina Tacconelli combines the information from clinical, microbiological and basic research. Scientists and physicians are working closely together to tackle the problem of increasing antibiotic-resistant germs in hospitals. Samples are collected in clinical ...

Tübingen

Clinical Trials Platform

The Clinical Trials Platform at the Tübingen Institute of Tropical Medicine supports the development of new agents and vaccines against infectious diseases. It focuses on conducting experimental studies and first trials on humans. A special feature is the human malaria infection model, developed in ...

Hamburg - Lübeck - Borstel - Riems

Clinical Tuberculosis Centre

The Clinical Tuberculosis Centre provides the expertise and infrastructure for the optimisation, prevention, diagnosis and treatment of tuberculosis (TB) as well as for translating research results into clinical practice. The main objectives of the Clinical Tuberculosis Centre include coordinating ...